Current and historical daily PE Ratio for Carl Zeiss Meditec AG (
LTS:0DHC
) from 2007 to May 15 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Carl Zeiss Meditec AG stock (LTS:0DHC) PE ratio as of May 15 2024 is 31.74.
More Details
Carl Zeiss Meditec AG (LTS:0DHC) PE Ratio (TTM) Chart
Carl Zeiss Meditec AG (LTS:0DHC) PE Ratio (TTM) Historical Data
View and export this data going back to 2007. Start your Free Trial
Total 1253
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Carl Zeiss Meditec AG PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-15 | 32.4 | 2024-03-08 | 38.8 |
| 2024-05-14 | 32.4 | 2024-03-07 | 37.3 |
| 2024-05-13 | 31.8 | 2024-03-06 | 37.3 |
| 2024-05-10 | 32.6 | 2024-03-05 | 38.3 |
| 2024-05-09 | 32.0 | 2024-03-04 | 37.6 |
| 2024-05-08 | 32.2 | 2024-03-01 | 37.3 |
| 2024-05-07 | 33.8 | 2024-02-29 | 36.6 |
| 2024-05-03 | 33.6 | 2024-02-28 | 35.8 |
| 2024-05-02 | 33.5 | 2024-02-27 | 35.8 |
| 2024-05-01 | 33.7 | 2024-02-26 | 36.2 |
| 2024-04-30 | 33.7 | 2024-02-23 | 36.9 |
| 2024-04-29 | 34.3 | 2024-02-22 | 36.2 |
| 2024-04-26 | 34.4 | 2024-02-21 | 35.9 |
| 2024-04-25 | 33.9 | 2024-02-20 | 36.0 |
| 2024-04-24 | 34.5 | 2024-02-19 | 35.9 |
| 2024-04-23 | 34.9 | 2024-02-16 | 35.6 |
| 2024-04-22 | 33.7 | 2024-02-15 | 35.6 |
| 2024-04-19 | 33.1 | 2024-02-14 | 36.0 |
| 2024-04-18 | 33.3 | 2024-02-13 | 35.0 |
| 2024-04-17 | 33.0 | 2024-02-12 | 35.4 |
| 2024-04-16 | 34.9 | 2024-02-09 | 35.8 |
| 2024-04-15 | 35.5 | 2024-02-08 | 34.0 |
| 2024-04-12 | 35.1 | 2024-02-07 | 33.5 |
| 2024-04-11 | 35.2 | 2024-02-06 | 33.2 |
| 2024-04-10 | 35.6 | 2024-02-05 | 32.4 |
| 2024-04-09 | 36.3 | 2024-02-02 | 33.1 |
| 2024-04-08 | 36.3 | 2024-02-01 | 33.0 |
| 2024-04-05 | 36.6 | 2024-01-31 | 31.8 |
| 2024-04-04 | 37.6 | 2024-01-30 | 32.0 |
| 2024-04-03 | 38.2 | 2024-01-29 | 32.4 |
| 2024-04-02 | 39.1 | 2024-01-26 | 31.6 |
| 2024-03-28 | 39.7 | 2024-01-25 | 31.9 |
| 2024-03-27 | 38.6 | 2024-01-24 | 31.8 |
| 2024-03-26 | 38.3 | 2024-01-23 | 31.7 |
| 2024-03-25 | 38.4 | 2024-01-22 | 31.9 |
| 2024-03-22 | 38.1 | 2024-01-19 | 32.2 |
| 2024-03-21 | 37.6 | 2024-01-18 | 33.1 |
| 2024-03-20 | 37.4 | 2024-01-17 | 33.0 |
| 2024-03-19 | 38.5 | 2024-01-16 | 33.0 |
| 2024-03-18 | 38.5 | 2024-01-15 | 33.1 |
| 2024-03-15 | 39.5 | 2024-01-12 | 33.3 |
| 2024-03-14 | 39.3 | 2024-01-11 | 33.4 |
| 2024-03-13 | 39.6 | 2024-01-10 | 32.1 |
| 2024-03-12 | 38.7 | 2024-01-09 | 32.6 |
| 2024-03-11 | 38.6 | 2024-01-08 | 31.6 |
Carl Zeiss Meditec AG (LTS:0DHC) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Carl Zeiss Meditec AG
ISIN : DE0005313704
Share Class Description:
LTS:0DHC: Ordinary SharesCompare
Compare
Traded in other countries / regions
AFX.Germany0DHC.UKCZMWY.USA1AFX.ItalyAFX.AustriaAFX.SwitzerlandAFX.Mexico IPO Date
2007-12-14Description
Carl Zeiss Meditec is one of the largest medical technology companies in the world and it operates in two segments: Ophthalmic devices and Microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers